Skip to main content
. 2018 Nov 29;6:133. doi: 10.1186/s40425-018-0445-4

Fig. 2.

Fig. 2

NK-mediated lysis of BRCA mutant prostate carcinoma cells treated with olaparib is further increased by the addition of an ADCC-mediating antibody. a Real-time impedance-based cell analysis of BRCA mutant (mut) prostate carcinoma (22RV1) cells in the presence or absence of olaparib (ola) and human NK cells, treated with either cetuximab (cet) or isotype control. b 22RV1 cells lysed with or without olaparib pretreatment and NK cells, treated with either cetuximab or isotype control at 12 h and 36 h. This experiment was performed with four different human NK donors with similar results. p < 0.001***, p < 0.0001****